AR086241A1 - Proteinas repetitivas de union a il4/il13 y usos - Google Patents

Proteinas repetitivas de union a il4/il13 y usos

Info

Publication number
AR086241A1
AR086241A1 ARP120101543A ARP120101543A AR086241A1 AR 086241 A1 AR086241 A1 AR 086241A1 AR P120101543 A ARP120101543 A AR P120101543A AR P120101543 A ARP120101543 A AR P120101543A AR 086241 A1 AR086241 A1 AR 086241A1
Authority
AR
Argentina
Prior art keywords
binding
domain
protein
diseases
binding domain
Prior art date
Application number
ARP120101543A
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Molecular Partners Ag filed Critical Janssen Biotech Inc
Publication of AR086241A1 publication Critical patent/AR086241A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Reivindicación 1: Una proteína de unión que comprende un dominio de unión, en donde el dominio de unión es un dominio con repeticiones de anquirina que se une a la IL4 humana e inhibe la unión de IL4 a IL4Ra in vitro o in vivo y en donde el dominio con repeticiones de anquirina comprende por lo menos un módulo con repeticiones de anquirina.Reivindicación 32: La composición farmacéutica de conformidad con la reivindicación 28, en donde la composición está formulada para el suministro con el uso de un nebulizador. Reivindicación 40: Una proteína de unión que comprende un dominio de unión, en donde el dominio de unión es un dominio con repeticiones de anquirina, en donde la proteína de unión compite para unirse a la proteína IL4 que tiene la secuencia de aminoácidos de la sec. con núm. de ident.: 4 y/o la proteína IL13 tiene la secuencia de aminoácidos de la sec. con núm. de ident.: 101, con la proteína de unión de cualquiera de la reivindicaciones 1 - 7, 9 - 18 y 20 - 27. Reivindicación 47: El uso de un dominio de unión de conformidad con cualquiera de las reivindicaciones 1 - 7, 9 - 18, 20 - 27 y 41 para elaborar un medicamento para tratar enfermedades cardiovasculares, enfermedades respiratorias, cáncer, enfermedades dermatológicas y enfermedades fibróticas.
ARP120101543A 2011-04-29 2012-05-02 Proteinas repetitivas de union a il4/il13 y usos AR086241A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481008P 2011-04-29 2011-04-29
US201161480999P 2011-04-29 2011-04-29
US201161481021P 2011-04-29 2011-04-29

Publications (1)

Publication Number Publication Date
AR086241A1 true AR086241A1 (es) 2013-11-27

Family

ID=47068346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101543A AR086241A1 (es) 2011-04-29 2012-05-02 Proteinas repetitivas de union a il4/il13 y usos

Country Status (14)

Country Link
US (2) US8722618B2 (es)
EP (1) EP2702069A4 (es)
JP (1) JP2014519808A (es)
KR (1) KR20140039203A (es)
CN (1) CN104105704A (es)
AR (1) AR086241A1 (es)
AU (1) AU2012249359A1 (es)
BR (1) BR112013027766A2 (es)
CA (1) CA2834624A1 (es)
EA (1) EA201391607A1 (es)
IL (1) IL229093A0 (es)
TW (1) TW201305337A (es)
UY (1) UY34048A (es)
WO (1) WO2012149439A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
ES2758352T3 (es) * 2010-11-26 2020-05-05 Molecular Partners Ag Proteínas de repetición diseñadas que se une a la seroalbúmina
AU2013283296A1 (en) * 2012-06-28 2015-02-05 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3004152B1 (en) * 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018195388A1 (en) * 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
KR20200011685A (ko) * 2018-07-25 2020-02-04 주식회사유한양행 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도
WO2020190852A2 (en) * 2019-03-17 2020-09-24 Jorge Fallas Topological control of receptor signaling using synthetic homo- and hetero-dimeric cytokine mimetics
MX2021014601A (es) * 2019-06-04 2022-02-11 Molecular Partners Ag Proteinas recombinantes de union a fap y su uso.
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
MX2022007122A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
CA3176845A1 (en) 2020-05-06 2021-11-11 Patrick AMSTUTZ Novel ankyrin repeat binding proteins and their uses
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
CN116789843A (zh) * 2022-03-16 2023-09-22 伯桢生物科技(杭州)有限公司 Wnt重组蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
AU775997B2 (en) 1998-12-02 2004-08-19 Bristol-Myers Squibb Company DNA-protein fusions and uses thereof
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
CA2614512C (en) 2005-07-08 2014-01-07 University Of Zuerich Phage display using cotranslational translocation of fusion polypeptides
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
KR20090064559A (ko) 2006-10-16 2009-06-19 (주)제이슨알앤디 콘텐츠 부가정보를 전송하는 시스템 및 이용방법
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction

Also Published As

Publication number Publication date
UY34048A (es) 2012-10-31
KR20140039203A (ko) 2014-04-01
TW201305337A (zh) 2013-02-01
WO2012149439A2 (en) 2012-11-01
EP2702069A4 (en) 2015-04-29
US8722618B2 (en) 2014-05-13
JP2014519808A (ja) 2014-08-21
AU2012249359A1 (en) 2013-11-14
CA2834624A1 (en) 2012-11-01
US9206244B2 (en) 2015-12-08
CN104105704A (zh) 2014-10-15
BR112013027766A2 (pt) 2016-11-29
EP2702069A2 (en) 2014-03-05
EA201391607A1 (ru) 2014-04-30
IL229093A0 (en) 2013-12-31
US20140206599A1 (en) 2014-07-24
WO2012149439A3 (en) 2014-05-30
US20120277143A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
AR086241A1 (es) Proteinas repetitivas de union a il4/il13 y usos
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CO6400149A2 (es) Proteínas de enlace a miostatina
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
ECSP12012272A (es) Proteínas que se unen al tnf-?
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
CO6551686A2 (es) Inmunoglobinas con dominio variable dual y usos de las mismas
BR112012030664A2 (pt) proteína de ligação de antígeno humanizada, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de uma proteína de ligação de antígeno, para tratar um indivíduo afligido com uma doença e para aumentar a massa muscular, aumentar a força muscular, e/ou melhorar a função muscular em um paciente, e, composição farmacêutica.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
BR112014007675A2 (pt) tratamento de doença articular degenerativa
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2

Legal Events

Date Code Title Description
FB Suspension of granting procedure